Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Phase 3 Completed 6 enrolled Merck Sharp & Dohme LLC

NaSingle-groupOpen-labelTreatment

Summary

The clinical trial objectives were to evaluate the dialysability of the sugammadex-rocuronium complex; it's safety and efficacy in participants with severe renal impairment.

Timeline

Start: 2008-04
Primary completion: 2009-07
Completion: 2009-07

Publications

Results Cammu G, Van Vlem B, van den Heuvel M, Stet L, el Galta R, Eloot S, Demeyer I. Dialysability of sugammadex and its complex with rocuronium in intensive care patients with severe renal impairment. Br J Anaesth. 2012 Sep;109(3):382-90. doi: 10.1093/bja/aes207. Epub 2012 Jun 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rocuronium	Other / unclassified	0.6 mg/kg	Intravenous
Subject	Sugammadex	Other / unclassified	4 mg/kg	Intravenous

Indications

No indication recorded.